Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01342289

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This research is being done to learn more about nonmyeloablative bone marrow transplantation (BMT), also known as a "mini" transplant for patients with blood cancers, using bone marrow from a relative.

Status: 
Recruiting
Study Date: 
Fri, 07/01/2011 to Fri, 06/01/2018
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Procedure: Bone Marrow Transplant Preparative regimen consists of Fludarabine - 30 mg/m2/day , Cytoxan - 14.5 mg/kg/day , and Total Body Irradiation administered in a single fraction , with posttransplantation high-dose Cytoxan - 50 mg/kg IV, Mycophenolate mofetil - 15 mg/kg PO TID, and tacrolimus- starting dose is 1 mg IV QD. Other Names: Fludara Cyclophosphamide TBI High-dose Cy MMF Tacrolimus BMT